FDA Warns Reliance Life Sciences Over Falsified Lab Records

Microbiology laboratory records at Reliance Life Sciences Private Limited contained fabricated incubation entries and miscalculated microbial limit test results, according to an FDA warning letter dated August 18, 2026, issued following a February inspection of the firm's Navi Mumbai, Maharashtra facility (FEI 3009510975). The findings carry adulteration status under section 501(a)(2)(B) of the FD&C Act, placing distributed product batches under immediate scrutiny.

During the February 19–27, 2026 inspection, investigators found that environmental monitoring and additional sample plates documented in logbooks as collected and incubated could not be located in incubators. Analyst interviews confirmed the samples were never collected. Colony forming unit counts had been entered as though incubation was actively in progress, a pattern FDA characterised as indicative of systematic underreporting of microbial contamination risk.

A compounding deficiency in the facility's Laboratory Information Management System (LIMS) further undermined batch release integrity. Required dilution factors were absent from microbial limit test calculations, meaning batches were released against raw plate count averages rather than concentration-adjusted figures aligned with compendial methods and the firm's own procedures. Under 21 CFR 211.194(a), laboratory records must include complete data from all tests necessary to confirm specification compliance, a standard the current LIMS configuration does not meet.

For QA directors and microbiology lab managers at finished-dose and API sites supplying the US market, the inspection record reinforces a well-documented FDA enforcement pattern: LIMS configuration gaps and manual logbook entries without corresponding physical evidence are treated not as isolated procedural lapses but as indicators of systemic data integrity failure. Remediation responses that address individual incidents without root-cause analysis of the data governance framework have consistently drawn further regulatory action.

Reliance Life Sciences submitted a response to the Form FDA 483 on March 20, 2026; FDA reviewed it and found it insufficient to close the violations. The agency's warning letter explicitly reserves the right to take regulatory action without further notice if corrections are not adequately implemented.

The measurable remediation checkpoint will be whether the firm's CAPA documentation demonstrates validated LIMS configuration changes, verified sample chain-of-custody controls, and independent audit confirmation before any resumption of normal US-market batch release.

Source: FDA Center for Drug Evaluation and Research (CDER) via FDA.gov Warning Letters feed, September 1, 2026. Warning letter reference number 320-26-117; inspection dates February 19–27, 2026.